Figure 2
From: Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma
The prognosis efficiency of DCTD. (A) The prognosis efficiency of DCTD in all WHO grade III and IV (except for the screening group, additional patients whose survival time is between 1 to 3 years were included, and the total number of samples was 178) patients in CGGA transcriptional microarray data and WHO grade III and IV glioma in CGGA RNA-seq data. (B) The prognosis efficiency of DCTD in GBM (n = 512) from TCGA transcriptional microarray data that were updated in 2013, which was expanded from the dataset that we used to search for the 7 genes and in GBM (n = 393) from TCGA RNA-seq dataset. (C) The prognosis efficiency of DCTD validated in GSE16011 and REMBRANDT datasets. (D) The ROC curves indicating the sensitivity and specificity of predicting 5 years of survival with DCTD-level in CGGA and TCGA database. (E) The ROC curves indicating the sensitivity and specificity of predicting 3 years of survival with DCTD-level in CGGA and TCGA database.
